Current Landscape of SCS Research

Spinal Cord Stimulation Clinical Trials Evaluating Efficacy and Long Term Outcomes

Spinal cord stimulation clinical trials represent the definitive method for evaluating whether this neuromodulation therapy can safely and effectively disrupt pain signals before they reach the brain. By implanting a small device that delivers precisely controlled electrical pulses to the spinal cord, these trials directly test the ability to replace chronic pain with a more tolerable tingling sensation. The primary benefit proven through rigorous clinical protocols is a clinically meaningful reduction in pain intensity, often enabling patients to decrease their reliance on opioid medications and restore daily function.

Current Landscape of SCS Research

The current landscape of spinal cord stimulation clinical trials is shifting focus toward refining patient selection and optimizing closed-loop stimulation systems. Trials now test real-time feedback algorithms that adjust pulse parameters based on spinal cord recording, aiming to reduce paresthesia and improve efficacy for chronic pain. Another active area is the use of directional leads and high-frequency waveforms in sham-controlled studies to isolate placebo effects. Researchers are also enrolling more diverse cohorts to validate outcomes across different pain etiologies, moving beyond traditional failed back surgery syndrome. To keep trials practical, endpoints increasingly prioritize patient-reported quality of life and functional gains, not just pain scores. This pragmatic approach helps translate findings into more predictable, everyday clinical benefits.

Key conditions under investigation in new studies

New clinical trials are zeroing in on refractory pain conditions beyond standard failed back surgery syndrome. Investigators are rigorously examining chronic pelvic pain, often from endometriosis or interstitial cystitis, where SCS may interrupt visceral nociception. Another frontier is painful diabetic neuropathy, with studies targeting lower extremity burning and numbness. Additionally, trials are exploring post-amputation phantom limb pain and complex regional pain syndrome. The sequence of evaluation follows a structured pathway:

1. Screening for neuropathic pain etiology via quantitative sensory testing
2. Implanting temporary leads for a 7-day trial period with 50% pain reduction threshold
3. Evaluating functional outcomes like gait improvement and opioid reduction

Each study employs distinct stimulation parameters—burst, high-frequency, or closed-loop—to isolate efficacy for these specific diagnoses.

Evolution from traditional to closed-loop systems

The evolution from traditional open-loop spinal cord stimulation to closed-loop adaptive systems in clinical trials focuses on real-time, physiological feedback. Traditional systems deliver fixed parameters, often causing over- or under-stimulation due to postural changes. Closed-loop trials dynamically adjust stimulation intensity by sensing spinal cord evoked compound action potentials (ECAPs). This transition typically involves a sequence:

1. Implantation of leads with recording electrodes alongside stimulating contacts.
2. Algorithm calibration to detect neural response thresholds.
3. Automated adjustment of pulse amplitude or frequency to maintain target ECAP amplitude during movement.

Trials compare rates of paresthesia-free pain relief and positional stability against fixed-output controls.

Design and Methodology in Recent Trials

Recent SCS trials are ditching old crossover designs for multi-arm parallel groups, allowing direct comparison between different stimulation parameters. You’ll see more pragmatic, real-world settings instead of strict academic labs, with longer follow-ups (12–24 months) to catch delayed effects or device failures. A short inline Q&A: *”Why do some trials now randomize by paresthesia vs. subperception?”* – Because it isolates which waveform actually drives pain relief, avoiding bias from the classic “tingling equals working” assumption. Blinding is still hard, but a few trials use sham implants or inactive remote controls for controls, though participants often guess anyway. Outcome sets now prioritize patient-reported function (walking, sleep) over just pain scores.

Randomized controlled vs. observational approaches

Recent spinal cord stimulation (SCS) trials increasingly favor pragmatic randomized controlled designs over observational approaches to establish true treatment efficacy. Randomized trials, such as those employing sham stimulation or delayed-onset controls, directly eliminate placebo and selection bias, proving causal effect on pain reduction. Observational studies, while useful for long-term safety, suffer from confounding by indication—patients with better prognoses often choose SCS. The practical difference for clinicians is clear: randomized evidence provides higher confidence for predicting patient outcomes, whereas observational data only highlights associations.

Randomized controlled trials validate SCS causality; observational studies only suggest correlation.

Blinding techniques and sham stimulation controls

Recent spinal cord stimulation trials employ sham stimulation controls to mitigate placebo effects, typically using sub-perception or brief, random pulses that patients cannot distinguish from active therapy. Blinding is achieved through device programming that masks clinician and participant allocation, though maintaining integrity remains challenging due to paresthesia sensations. A clear sequence for implementing these controls includes:

1. Programming a sham parameter set (e.g., 0 Hz, 1 µs pulse width) that delivers no therapeutic current.
2. Enabling clinician-blinded randomization via encrypted remote controllers.
3. Conducting post-trial debriefings to assess blinding success through participant guesses.

Proper sham validation requires demonstrating equivalent threshold perception between active and sham arms.

Patient-reported outcomes and biomarker endpoints

Recent spinal cord stimulation trials increasingly integrate patient-reported outcomes and biomarker endpoints to capture both subjective relief and objective physiological changes. Patient-reported outcomes, such as pain intensity scales and quality-of-life questionnaires, directly quantify the user’s perceived benefit, while biomarker endpoints—like quantitative sensory testing or neuroimaging biomarkers—provide measurable, verifiable data on nervous system response. This dual approach strengthens trial validity by correlating what patients feel with what the body shows.

• Patient-reported outcomes track real-world symptom changes in pain and function.
• Biomarker endpoints offer objective metrics like nerve conduction or cortical activation shifts.
• Combining both reduces placebo ambiguity and confirms treatment-specific neurological impact.

Patient Selection and Enrollment Criteria

Patient selection for spinal cord stimulation (SCS) trials hinges on a confirmed diagnosis of chronic neuropathic pain, such as failed back surgery syndrome or complex regional pain syndrome, with a documented failure of conservative management and no untreated major psychiatric comorbidities. Enrollment criteria typically require a minimum pain duration of 6–12 months, a baseline Visual Analog Scale score ≥5/10, and a successful psychological screening to rule out somatization or active substance abuse. A key exclusion is ongoing anticoagulation therapy that cannot be paused for the temporary lead placement. Q: What is the most critical enrollment criterion? A: Objective evidence of a neuropathic pain generator, as SCS fails against nociceptive or mechanical causes. Final enrollment often mandates a trial period of 3–7 days with a 50% or greater pain reduction before permanent implantation is offered.

Inclusion of failed back surgery syndrome cohorts

The inclusion of failed back surgery syndrome cohorts in spinal cord stimulation trials typically requires patients to have persistent radicular pain for at least six months post-surgery, with clear evidence of non-surgical scarring or arachnoiditis on imaging. Enrollment criteria often specify a minimum baseline pain score of 5/10 on the visual analog scale, alongside failed conservative therapies like physical therapy or nerve blocks. These cohorts are stratified by prior surgical history, as single-level failures may respond differently than multilevel fusion failures. Exclusion criteria usually bar those with untreated opioid dependence or active spinal instability, ensuring the cohort’s homogeneity for accurate outcome measurement. A comparison of common inclusion thresholds:

Expanding indications for complex regional pain syndrome

Expanding indications for complex regional pain syndrome within spinal cord stimulation trials now includes enrollment of patients with earlier-stage CRPS, before chronic dystrophic changes manifest. Recent protocols specifically target type I CRPS populations previously excluded, leveraging novel CRPS subtyping criteria to identify responders. Enrollment criteria are narrowing from broad limb pain to distinct sensory-motor profiles, improving trial homogeneity. This shift allows earlier intervention, stopping disease progression before irreversible trophic damage, while excluding patients with only minor trauma history to isolate genuine neuropathic mechanisms.

Expanding indications for complex regional pain syndrome now prioritizes early, subtype-specific CRPS patients to optimize spinal cord stimulation outcomes before chronic structural changes occur.

Excluding common comorbidities for cleaner data

Excluding common comorbidities is essential for obtaining cleaner clinical trial data in spinal cord stimulation studies. Conditions like diabetes, fibromyalgia, or prior spinal surgery are often excluded because their neuropathic components can independently alter pain perception, creating confounding variables. This strict screening ensures that any observed analgesic effect is primarily attributable to the SCS device, not an underlying disease process. It also reduces variability in baseline pain scores and minimizes risk of implantation site infections or paresthesia interference. By narrowing the cohort to patients with only the target indication, researchers improve statistical clarity and causal inference from the collected outcome measures.

Technological Innovations Being Tested

The hum of the lab is punctuated by a patient’s gasp as a new closed-loop algorithm fires in real-time, adjusting stimulation current based on her spinal cord’s live neural feedback. In these clinical trials, innovations like optogenetics are being tested, where light, not electricity, targets specific neuron clusters to reduce side effects. Advanced electrode arrays now map spinal topography with single-micron precision, allowing doctors to steer current around damaged tissue. One trial participant, gripping a walker, asked, “How does the system know which nerves to wake up?” The answer: a machine-learning model, trained on his gait data, predicts his intended movement and adjusts the burst patterns before he even takes a step. These trials test not just relief, but the restoration of coordinated motion.

High-frequency and burst stimulation paradigms

Clinical trials are rigorously evaluating high-frequency and burst stimulation paradigms to optimize paresthesia-free pain relief. High-frequency (10 kHz) therapy is tested for its ability to cover broad pain maps without the paresthesia typical of traditional stimulation. Burst stimulation, delivering packets of high-frequency pulses followed by a quiescent period, is being compared against tonic stimulation for improved limb pain coverage and reduced sensation of stimulation.

• 10 kHz high-frequency paradigms are being assessed for superior efficacy in treating back and leg pain without paresthesia.
• Burst stimulation trials focus on its potential to modulate the medial pain pathway, targeting affective-emotional components of chronic pain.
• Trial protocols compare patient-reported outcomes for burst versus tonic paradigms to establish optimal duty cycles and amplitude settings.

Dorsal root ganglion targeting strategies

Clinical trials are refining dorsal root ganglion targeting strategies to overcome the limitations of broad epidural stimulation. By positioning leads precisely over the DRG, researchers achieve highly selective activation of individual dermatomes, drastically reducing paresthesia overlap. This granular approach directly addresses painful focal neuropathies, such as post-surgical or diabetic foot pain, where traditional SCS fails. Current protocols test steerable leads and intermittent, low-threshold waveforms to map each ganglion’s unique sensory footprint, aiming to eliminate unnecessary muscle twitching and allow patients to maintain therapy without positional side effects during daily movement.

Wireless and rechargeable implant updates

In current spinal cord stimulation trials, wireless and rechargeable implant updates focus on eliminating percutaneous leads and external battery packs. New systems use inductive coupling to transmit power transdermally, allowing the implanted pulse generator to be fully subcutaneous and rechargeable without requiring reoperation for battery depletion. Trials assess whether smaller, wirelessly charged units can maintain consistent signal delivery while reducing infection risks from transcutaneous wires. Some updates integrate bidirectional telemetry, letting clinicians adjust stimulation parameters wirelessly without patient travel.

Wireless and rechargeable implant updates remove external hardware, enable transdermal power thync.com transfer, and support remote parameter adjustments in spinal cord stimulation trials.

Safety and Adverse Event Reporting

In spinal cord stimulation clinical trials, rigorous adverse event reporting is essential for patient safety. You must document any device-related complications, such as lead migration, infection at the implant site, or unexpected paresthesia changes, immediately. Standardized reporting forms collect data on severity, timing, and relationship to the investigational device. Note that a transient stimulation discomfort not meeting the serious adverse event threshold still warrants a complete report to track patterns. Every event requires a clear causal assessment by the clinical team and, if applicable, prompt unmasked adjudication. Consistent reporting ensures early identification of safety signals, guiding protocol modifications or trial suspension when necessary to protect participants.

Lead migration and infection rate benchmarks

In spinal cord stimulation clinical trials, lead migration and infection rate benchmarks are critical safety endpoints. Lead migration benchmarks typically target a 1–5% incidence over the trial period, measured via radiographic confirmation of electrode displacement exceeding a vertebral level. Infection rate benchmarks demand a surgical site infection rate below 2% for temporary leads and under 5% for permanent implants. These benchmarks are established from pooled historical data and used to monitor adverse events. A clear sequence for benchmark application follows:

1. Define migration as >2mm displacement from the initial stimulation target.
2. Classify infections as superficial (within 30 days) or deep (requiring explant).
3. Compare observed rates against the predefined thresholds for safety signal triggering.

Neurological deficits and complication management

In spinal cord stimulation clinical trials, neurological deficits such as new-onset weakness, paresthesia changes, or bowel/bladder dysfunction demand immediate protocol-driven assessment to differentiate transient lead migration from permanent nerve injury. Complication management algorithms prioritize electrode repositioning or explantation if imaging confirms compression or hematoma, while temporary stimulation cessation and high-dose corticosteroids are deployed for suspected edema. Serial neurological exams and neurophysiological monitoring track recovery, with trial protocols mandating urgent neurosurgical consultation for progressive deficits. Adverse event reporting must document the deficit’s severity, onset timing, and intervention response to refine future lead placement and safety thresholds.

Long-term safety data from extended follow-ups

Extended follow-ups in spinal cord stimulation trials provide critical long-term safety data by tracking adverse events beyond the initial implant period. These data reveal that lead migration and fracture risks often emerge after the first year, while infection rates plateau. Electrode array failure accounts for a gradual rise in revision surgeries beyond 24 months. Stimulation-related discomfort and battery depletion also accumulate, necessitating periodic reprogramming or replacement. The absence of progressive neurological damage in longer cohorts supports the intervention’s tolerability, though patient attrition in follow-up complicates absolute risk assessment.

Long-term safety data from extended follow-ups confirms that lead-related mechanical failures and battery depletion are the dominant delayed adverse events, while infection and neurological harm remain low over 2–5 years.

Efficacy Outcomes Across Pain Types

In spinal cord stimulation clinical trials, efficacy outcomes across pain types show distinct patterns. For neuropathic pain, particularly failed back surgery syndrome and complex regional pain syndrome, trials consistently report ≥50% pain relief in over half of patients at 12 months. Nociceptive pain outcomes are less robust, with studies demonstrating moderate reductions in axial low back pain. For diabetic peripheral neuropathy, recent high-frequency trials show significant improvement, with 72% of patients achieving ≥50% pain reduction at 3 months. Mixed pain etiologies present variable results; trials stratify patients by predominant pain type to better predict responder rates, using outcome measures like the Visual Analog Scale and Oswestry Disability Index to quantify type-specific efficacy.

Neuropathic vs. nociceptive pain response rates

In spinal cord stimulation trials, response rates diverge sharply between pain types. Neuropathic pain, particularly from failed back surgery syndrome, consistently shows 50–70% responder rates, while nociceptive pain rarely exceeds 30% in controlled settings. Neuropathic pain response rates remain the primary metric for SCS efficacy. This disparity often stems from SCS preferentially modulating central sensitization rather than acute peripheral nociceptor signals. Why does nociceptive pain respond so poorly? Because SCS primarily alters spinal gate mechanisms targeting neuropathic pathways, leaving nociceptive, inflammation-driven signals largely unaffected in most trial cohorts.

Changes in medication usage and quality of life scores

In spinal cord stimulation trials, many patients see a clear shift in their daily routines, specifically through reduced opioid dependency. Medication usage often drops significantly as the device covers more pain, which directly parallels improvements in quality of life scores. Participants report less brain fog and more energy, as they’re not balancing heavy painkiller side effects with constant discomfort. It’s a practical win: less reliance on pills usually means better sleep, mood, and mobility.

• Opioid consumption typically decreases by 30–50% among responders.
• Quality of life scores (like SF-36 or EQ-5D) often improve alongside reduced pill intake.
• Many patients cite fewer “breakthrough” pain episodes, so they skip rescue medications.
• Reduced sedation from fewer drugs contributes directly to higher daily activity scores.

Sustained pain relief beyond twelve months

Clinical trials tracking sustained pain relief beyond twelve months reveal that responders often maintain a 50% or greater reduction in baseline pain scores through two- and five-year follow-ups. In failed back surgery syndrome studies, approximately 60-70% of participants who achieved initial success retained that benefit, demonstrating durable neuro-adaptive modulation rather than temporary masking. Notably, trial outcomes for complex regional pain syndrome show comparable longevity, with pain intensity remaining significantly lower than pre-implant baselines. These long-term data directly inform patient expectations, confirming that spinal cord stimulation can produce non-reversible analgesic effects when properly titrated.

Beyond twelve months, spinal cord stimulation trials confirm that 60-70% of responders maintain at least 50% pain reduction, offering durable reprieve through neuro-adaptive remodeling rather than transient relief.

Pediatric and Geriatric Subgroup Analyses

In spinal cord stimulation clinical trials, pediatric and geriatric subgroup analyses are crucial because these age groups differ significantly from the general adult population in physiology and pain perception. For geriatric patients, trials examine how age-related nerve degeneration and comorbidities affect stimulation thresholds and long-term efficacy. Pediatric analyses, though rarer, focus on safety and growth-adjusted lead placement, as children’s smaller anatomy requires customized programming. A key insight from these studies is that older adults often require lower stimulation frequencies to avoid discomfort, while children may need more frequent device adjustments as they grow.

Without these subgroup analyses, clinical outcomes risk being either undertreated or overtolerated in these vulnerable populations.

Practical data from these analyses guide clinicians on battery life expectations and acceptable paresthesia coverage.

Age-related differences in trial participation

Age-related differences in trial participation for spinal cord stimulation reveal distinct physiological and practical barriers. Eligible older adults often show lower enrollment rates due to comorbidities and concerns about surgical risks under anesthesia, while pediatric candidates face stringent exclusion criteria related to spinal growth and device footprint. Younger participants may demonstrate higher dropout from implant site discomfort, whereas geriatric cohorts exhibit better compliance with follow-up but less tolerance for programming changes. This divergence necessitates stratified recruitment protocols that adjust for age-specific tolerance to electrode placement and stimulation titration. Without age-stratified designs, trial outcomes risk skewed efficacy data that misrepresents pain relief across generations.

Older adults enroll less due to surgical risks, children are excluded by spinal growth concerns—age directly dictates trial eligibility, retention, and stimulation response patterns.

Device tolerance and efficacy in older populations

In spinal cord stimulation clinical trials, assessing device tolerance in geriatric patients is key because older adults often have thinner skin and more comorbidities, making lead migration or infection slightly more common. Efficacy data shows older populations frequently report equal or better pain relief than younger groups, likely due to less physical activity causing fewer lead stresses. However, trials note that programming adjustments are often needed to avoid uncomfortable stimulation at lower amplitudes, as age-related nerve changes can heighten sensitivity. Overall, the devices work well but require a gentler, more careful initial setup for this group.

Older populations generally tolerate spinal cord stimulators well and achieve strong pain relief, though they need careful programming and monitoring due to age-related physiological changes.

Pediatric safety data from early-phase studies

Early-phase spinal cord stimulation trials in pediatrics prioritize pediatric safety data from early-phase studies, focusing on device-related adverse events and growth-related anatomical changes. A sequential analysis typically follows:

1. Initial dose-escalation cohorts assess acute neurological or hardware complications (e.g., lead migration, infection).
2. Short-term follow-up (≤6 months) evaluates pain response consistency and sensorimotor function preservation.
3. Adverse events are stratified by age subgroups (e.g., prepubescent vs. adolescent) to identify differential risks, such as dura thickening affecting electrode stability.

This tiered approach isolates safety signals distinct from adult data, directly guiding eligibility criteria for later-phase pediatric trials.

Regulatory and Reimbursement Implications

Navigating regulatory and reimbursement implications in spinal cord stimulation clinical trials means planning for FDA investigational device exemption (IDE) approval and coverage decisions upfront. You need to align trial endpoints—like pain reduction and quality of life—with requirements from payers such as Medicare, as they often demand long-term follow-up data before granting reimbursement for the implanted device. A key question: “What happens if the device fails during the trial?” The answer: your protocol must specify replacement costs and whether payers will cover explant surgery, or risk leaving patients with out-of-pocket bills. Always check local payer policies for temporary versus permanent implants, as missteps here can delay enrollment or stall coverage after market approval.

FDA approvals and breakthrough device designations

In spinal cord stimulation (SCS) clinical trials, FDA approval confirms that a device meets rigorous safety and efficacy benchmarks for its intended indication, allowing it to enter the U.S. market. A breakthrough device designation expedites this process, granting manufacturers earlier interactive review and priority FDA guidance. For trial participants, this designation means potential access to novel SCS systems, often for conditions lacking adequate therapies, while developers benefit from faster clinical data generation and a clearer regulatory pathway to market.

FDA approvals validate trial outcomes for market entry; breakthrough device designations accelerate development and review, offering earlier access to innovative SCS systems.

How trial results influence insurance coverage policies

Trial results directly shape insurance coverage policies by providing evidence of efficacy and safety. Positive outcomes, particularly from randomized controlled trials, often lead to expanded coverage criteria, such as reducing the mandatory trial period. Conversely, negative results showing no significant pain relief can prompt insurers to introduce stricter requirements, like requiring failed conservative therapy for a longer duration. The specific data on patient selection criteria from trials refines coverage policies. A clear sequence emerges:

1. Insurance reviews trial endpoints (e.g., pain reduction ≥50%, medication reduction).
2. Payout thresholds are set based on those benchmark results.
3. Coverage is restricted or broadened for patient subgroups that met those benchmarks.

This process ensures reimbursement aligns with proven patient benefit.

Post-market surveillance requirements for new systems

Once a new spinal cord stimulation system gains approval from a clinical trial, sponsors must initiate post-market surveillance requirements to monitor long-term safety and effectiveness. This entails a structured process: first, registry enrollment of all implanted patients to capture real-world adverse events. Second, periodic submission of updated clinical data, such as lead migration rates or infection incidence, to regulatory bodies. Third, analysis of battery longevity reports to identify premature failures. These sequential obligations ensure that any emerging risk profile from the trial cohort is promptly identified and communicated to clinicians, directly influencing continued device reimbursement eligibility.

Emerging Trends and Future Directions

In clinical trials for spinal cord stimulation, the emerging direction is toward closed-loop systems that adapt stimulation in real-time to neural feedback, moving beyond static, open-loop parameters. One investigator noted a patient whose trial showed a 60% pain reduction when the device automatically adjusted during movement. Q: What does real-time adaptation mean for trial outcomes? A: It allows researchers to capture dynamic, individual-specific responses, refining which neural signatures predicts long-term success. Future trials are now piloting biomarker-guided protocols, where spinal recordings during daily activity, not just lab tests, determine titration endpoints. This shifts the focus from general pain scores to personalized circuit modulation.

Personalized stimulation algorithms via machine learning

Personalized stimulation algorithms via machine learning are being tested in spinal cord stimulation (SCS) clinical trials to dynamically adapt parameters to patient-specific neural responses. These algorithms analyze real-time biomarkers, such as evoked compound action potentials, to autonomously optimize stimulation intensity for pain relief while minimizing paresthesia. In early-phase trials, this approach reduces the need for manual reprogramming, enabling a closed-loop system that adjusts to posture changes or diurnal pain fluctuations. Q: How do these algorithms determine the optimal dose? A: They compare incoming neural feedback against a personalized comfort threshold, using reinforcement learning to converge on settings that maximize analgesia without overstimulation.

Combination therapies with drug delivery systems

In spinal cord stimulation clinical trials, combination therapies with drug delivery systems are emerging to enhance analgesic efficacy. These protocols co-administer intrathecal agents—such as ziconotide or clonidine—via an implanted pump synchronized to the stimulator. The sequence typically follows: first, calibrate the drug infusion rate to the patient’s baseline pain; second, adjust stimulation parameters to exploit synergistic neural inhibition; and third, monitor for dose-sparing effects to reduce opioid dependency. This dual-modality approach targets both supraspinal and spinal pain pathways, offering sustained relief when SCS alone proves insufficient.

1. Initiate low-dose drug delivery simultaneous with SCS trial leads.
2. Iteratively titrate drug volumes while mapping paresthesia coverage.
3. Evaluate functional outcomes, then taper monotherapy reliance.

Home-based trial protocols and remote monitoring

Home-based trial protocols are shifting spinal cord stimulation research from the clinic into patients’ daily lives. By using wearable sensors and smartphone apps, investigators can now capture real-time pain scores and activity levels without requiring frequent site visits. This approach reduces participant burden while dramatically expanding data granularity. A remote monitoring infrastructure enables continuous, objective tracking of device usage patterns and therapy adjustments, ensuring patient compliance and safety outside controlled environments. These protocols accelerate enrollment and allow more diverse populations to participate, directly improving the relevance of trial outcomes for everyday clinical application.

What This Therapy Actually Entails in a Research Setting

How the implanted device interacts with your nervous system during a trial

Key differences between a clinical trial and standard treatment access

How to Qualify and Enroll in an Active Study

Typical inclusion criteria that determine your eligibility as a candidate

Steps to locate and apply for a nearby research program

What a Typical Trial Timeline Looks Like From Screening to Follow-Up

Phase breakdown: initial assessment, implant procedure, and trial period

Duration of the stimulation programming phase and what to expect daily

Practical Benefits You Can Expect From Participating

Access to cutting-edge stimulation patterns not yet publicly available

Potential for long-term pain relief without committing to permanent surgery

Choosing the Right Trial Based on Your Pain Profile

Comparing target areas: back, leg, or neuropathic conditions in different studies

Deciding between traditional paresthesia-based and subperception approaches

Common Questions Users Ask Before Joining

Will I have control over the stimulation settings during the study

What happens if the device provides no relief or causes discomfort